Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)

12 de novembro de 2026 atualizado por: Chuntao Gao, Tianjin Medical University Cancer Institute and Hospital

A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Concurrent Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)

This is a Phase I/II, single-arm, open-label, exploratory study aimed at evaluating the safety, tolerability, and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with gemcitabine and iparomlimab-toripalimab in patients with borderline resectable pancreatic cancer. The study is divided into two phases: The Phase Ib dose-escalation phase will use a "3+3" design to explore the maximum tolerated dose (MTD) of SBRT (6 Gy×5 F, 7 Gy×5 F, 8 Gy×5 F) combined with gemcitabine and iparomlimab-toripalimab. The Phase II phase will further evaluate the efficacy and safety of this combination regimen based on the SBRT dose determined in Phase Ib. The primary efficacy endpoint is the R0 resection rate.

Visão geral do estudo

Descrição detalhada

This is a single-center, Phase I/II, single-arm, open-label, exploratory clinical study initiated by Tianjin Medical University Cancer Institute & Hospital.

Phase Ib (Dose-Escalation Phase): A classic "3+3" design will be used to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of SBRT. Three pre-specified SBRT dose levels are planned: 6 Gy×5 F, 7 Gy×5 F, and 8 Gy×5 F. All subjects will concurrently receive standard-dose gemcitabine chemotherapy and iparomlimab-toripalimab immunotherapy. The DLT observation period is 6 months from the start of treatment, focusing on Grade 3 or higher SBRT-related toxicities in organs at risk. The MTD is defined as the highest dose level at which ≤33% (i.e., no more than 1 out of 6) of subjects experience a DLT during the observation period.

Phase II (Expansion Phase): Based on the SBRT MTD determined in Phase Ib, preoperative neoadjuvant therapy will be administered in combination with gemcitabine and iparomlimab-toripalimab. The treatment cycle consists of 3 cycles, expected to last 12 weeks. Tumor assessment will be performed after 2 cycles of treatment. If there is no disease progression and adverse reactions are tolerable, treatment will continue. Surgical resection will be performed 3-4 weeks after the last dose of chemotherapy and immunotherapy. Postoperatively, if the investigator determines the patient may benefit, adjuvant therapy will be administered, consisting of 4 cycles of gemcitabine chemotherapy and maintenance immunotherapy with iparomlimab-toripalimab for up to 1 year. The primary endpoint is the R0 resection rate.

Tipo de estudo

Intervencional

Inscrição (Estimado)

30

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Maobin Meng(Co-Principal Investigator), PhD
  • Número de telefone: 15202231270
  • E-mail: mmeng@tmu.edu.cn

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age ≥18 years and ≤75 years, both genders.
  2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
  3. Radiographically assessed as borderline resectable pancreatic cancer according to NCCN guidelines.
  4. At least one measurable lesion per RECIST v1.1 criteria.
  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  6. Adequate organ and bone marrow function.
  7. Expected survival ≥ 6 months.
  8. Voluntarily signed informed consent form.

Exclusion Criteria:

  1. Known distant metastases.
  2. Prior systemic anti-tumor therapy or radiotherapy for pancreatic cancer.
  3. Active autoimmune disease requiring systemic treatment within the past 2 years.
  4. History of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, non-melanoma skin cancer, or superficial bladder tumor.
  5. Uncontrolled comorbid conditions, including but not limited to active infections, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  6. Pregnant or lactating women.
  7. Any condition that, in the investigator's opinion, would make the subject unsuitable for participation in the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Iparomlimab-Tuvonralimab + Gemcitabine Group

Participants will receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1) combined with Gemcitabine (1000 mg/m², IV, D1 and D8) every 3 weeks for up to 6 cycles. After 6 cycles, participants without disease progression and with acceptable tolerance may continue to receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1, every 3 weeks) as maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or study termination.

Iparomlimab/Tuvonralimab (Code: QL1706) is a bispecific antibody targeting PD-1 and CTLA-4. It is administered by intravenous infusion at a dose of XX mg/kg once every 3 weeks until disease progression or unacceptable toxicity.

Gemcitabine (Brand name: Gemzar) is a nucleoside analogue chemotherapeutic agent. It is administered by intravenous infusion at a dose of 1000 mg/m² on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

SBRT is a highly precise form of radiation therapy that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues. It is administered in XX fractions over XX days/weeks.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Objective Response Rate, ORR
Prazo: From first dose to disease progression or study completion, up to approximately 24 months

Objective Response Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR) or partial response (PR).

From first dose to disease progression or study completion, up to approximately 24 months
Incidence of Adverse Events
Prazo: From first dose to 90 days after last dose, up to approximately 27 months

Incidence and severity of adverse events assessed by CTCAE v5.0, including treatment-related adverse events (TRAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs).

From first dose to 90 days after last dose, up to approximately 27 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Disease Control Rate, DCR
Prazo: From first dose to disease progression or study completion, up to approximately 24 months

Disease Control Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR), partial response (PR), or stable disease (SD).

From first dose to disease progression or study completion, up to approximately 24 months
Progression-Free Survival, PFS
Prazo: From first dose to disease progression or death, up to approximately 24 months

Progression-Free Survival assessed by RECIST v1.1, defined as the time from first dose to the first documentation of disease progression or death from any cause.

From first dose to disease progression or death, up to approximately 24 months
Overall Survival, OS
Prazo: From first dose to death or last follow-up, up to approximately 36 months

Defined as the time from first dose to death from any cause.

From first dose to death or last follow-up, up to approximately 36 months
Duration of Response, DOR
Prazo: From first documentation of response to disease progression or death, up to approximately 24 months

Duration of Response assessed by RECIST v1.1, defined as the time from the first documentation of complete response (CR) or partial response (PR) to the first documentation of disease progression or death from any cause.

From first documentation of response to disease progression or death, up to approximately 24 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Correlation between Biomarkers and Clinical Efficacy
Prazo: From first dose to study completion, up to approximately 36 months

To explore the correlation between biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI) status in tumor tissue and clinical efficacy endpoints including ORR, PFS, and OS.

From first dose to study completion, up to approximately 36 months
Quality of Life Assessment
Prazo: From baseline to 90 days after last dose, up to approximately 27 months

To evaluate changes in quality of life during and after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

From baseline to 90 days after last dose, up to approximately 27 months
Dynamic Changes of Peripheral Blood Immune Cell Subsets and Cytokines
Prazo: From first dose to disease progression or study completion, up to approximately 24 months

To explore the dynamic changes of peripheral blood immune cell subsets (CD3+, CD4+, CD8+ T cells, etc.) and cytokines (IL-6, TNF-α, IFN-γ, etc.) during treatment and their correlation with efficacy and adverse events.

From first dose to disease progression or study completion, up to approximately 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

30 de junho de 2028

Conclusão do estudo (Estimado)

20 de fevereiro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

12 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

This is a prospective, single-arm, single-center Phase II clinical study to evaluate the efficacy and safety of Iparomlimab/Tuvonralimab combined with gemcitabine in the treatment of locally advanced pancreatic cancer. The study plans to enroll 30 patients with histologically or cytologically confirmed locally advanced pancreatic ductal adenocarcinoma. Subjects will receive Iparomlimab/Tuvonralimab combined with gemcitabine until disease progression, intolerable toxicity, withdrawal of informed consent, or completion of 6 cycles of treatment. The primary endpoint is objective response rate (ORR), and secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever